| Literature DB >> 25649191 |
Motoh Iwasa1, Tomoaki Ishihara2, Rumi Mifuji-Moroka3, Naoki Fujita3, Yoshinao Kobayashi3, Hiroshi Hasegawa3, Kazuko Iwata4, Masahiko Kaito5, Yoshiyuki Takei3.
Abstract
Diabetes mellitus (DM), non-alcoholic fatty liver (NAFL), and obesity are associated with elevated branched-chain amino acid (BCAA) levels, but the mechanism and significance of this has not been elucidated. Eighty-four subjects were enrolled including 43 with DM. Serum BCAA levels were positively correlated with waist-hip ratio and ALT. Serum BCAA levels in subjects with DM were higher than non-DM and those in subjects with NAFL were also higher than non-NAFL. Treatment with pioglitazone and alogliptin (19 of 43 DM subjects) improved serum haemoglobin A1c and decreased BCAA levels. The decrease in BCAAs with improved glucose metabolism suggests that abnormal glucose metabolism is also a factor in elevated BCAA levels.Entities:
Keywords: Antidiabetic drug; Branched-chain amino acid; Diabetes mellitus; Non-alcoholic fatty liver; Obesity
Mesh:
Substances:
Year: 2015 PMID: 25649191 DOI: 10.1016/j.orcp.2015.01.003
Source DB: PubMed Journal: Obes Res Clin Pract ISSN: 1871-403X Impact factor: 2.288